| Mrs Nicole Marie Fritzky, CCC-SLP | |
|
32 Crescent Dr S, Andover, NJ 07821-4006 | |
| (973) 384-9124 | |
| Not Available |
| Full Name | Mrs Nicole Marie Fritzky |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 32 Crescent Dr S, Andover, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568623742 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 41YS00536600 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Nicole Marie Fritzky, CCC-SLP 32 Crescent Dr S, Andover, NJ 07821-4006 Ph: (973) 384-9124 | Mrs Nicole Marie Fritzky, CCC-SLP 32 Crescent Dr S, Andover, NJ 07821-4006 Ph: (973) 384-9124 |
News Archive
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
As reported in the journal Science, physicists at the Technische Universitaet Muenchen (TUM) and the University of Michigan have shown that synthetic membrane channels can be constructed through "DNA nanotechnology."
Scientists in Switzerland are uncovering new clues about how cancer cells grow - and how they can be killed - by studying stem cells, 'blank' cells that have the potential to develop into fully mature or 'differentiated' cells and other scientists in UK have made a breakthrough in understanding the cause of the most common form of childhood cancer, acute lymphoblastic leukaemia (ALL).
The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
Since the beginning of the COVID-19 pandemic, researchers have noted that women are generally less severely affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This has led to the exploration into estrogen and androgens' role in the hyperinflammatory clinical phenotypes of COVID-19. A recent study published on the preprint server bioRxiv shows that drugs targeting androgens and TMPRSS2 inhibitors may potentially combat the pandemic.
› Verified 3 days ago